SCHEMBL5890905

SCHEMBL5890905

Fc1ccc(-c2nn3c(N4CCOCC4)cc(Cl)cc3c2-c2ccnc(NC3CCCC3)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.57
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
MAPK14 Q16539 1/20 0.43
CDK4 P11802 2/20 0.42
GSK3B P49841 2/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPK1 P28482 4/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
MAPK3 P27361 1/20 0.41
IKBKB O14920 1/20 0.40
MAPK10 P53779 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5890491 0.93 CSNK1D (0.49) CSNK1DMAPK13MAPK12MAPK11MAPK14
SCHEMBL5890971 0.90 MAPK8 (0.49) CSNK1DMAPK13MAPK12MAPK11MAPK14
SCHEMBL5890649 0.85 CSNK1D (0.51) CSNK1DMAPK13MAPK12MAPK11MAPK14
SCHEMBL5891079 0.85 CSNK1D (0.50) CSNK1DMAPK13MAPK12MAPK11MAPK14
SCHEMBL5890640 0.84 CSNK1D (0.49) CSNK1DMAPK13MAPK12MAPK11MAPK14
SCHEMBL5875567 0.83 CSNK1D (0.54) CSNK1DMAPK13MAPK12MAPK11MAPK14
SCHEMBL6106877 0.82 CSNK1D (0.49) CSNK1DMAPK13MAPK12MAPK11MAPK14
SCHEMBL6107585 0.82 CAMK2D (0.45) CSNK1DCDK4GSK3BKDM4EALDH1A1
SCHEMBL6488667 0.82 CSNK1D (0.58) CSNK1DMAPK13MAPK12MAPK11MAPK14
SCHEMBL5457494 0.81 CSNK1D (0.51) CSNK1DMAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962914-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2005-11-08 US claimed
EP-1385847-B1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES SMITHKLINE BEECHAM CORP (US) 2005-06-01 EP claimed
US-7030134-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2006-04-18 US disclosed
US-6962914-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2005-11-08 US disclosed
US-20050192303-A1 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds GUDMUNDSSON KRISTJAN (US) 2005-09-01 US disclosed
EP-1385847-B1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES SMITHKLINE BEECHAM CORP (US) 2005-06-01 EP disclosed
US-20040142941-A1 Therapeutic compounds SMITHKLINE BEECHAM CORPORATION 2004-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142941-A1 Therapeutic compounds PCSK9, ABCB1, ABCB11 CSNK1D 466/4885MAPK13 4380/4885MAPK12 3686/4885
US-20050192303-A1 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds DPYD, TYMP, P2RY4 CSNK1D 479/4885MAPK13 1712/4885MAPK12 1225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.